Mizuho Securities USA Reiterates Buy Rating, $93 PT on Questcor Pharmaceuticals on Stock Price Weakness

Loading...
Loading...
In a report published Tuesday, Mizuho Securities USA analyst Mario Corso reiterated a Buy rating and $93.00 price target on
Questcor PharmaceuticalsQCOR
. In the report, Mizuho Securities USA noted, “In the wake of today's stock price weakness on short report that FTC will challenge Synacthen deal, we ascertained that QCOR hasn't received a formal FTC inquiry, and anything informal might just be in response to updated HSR guidelines. Even if FTC pursued a court challenge, could take 2+ years to decide, and most recent product case went in favor of acquirer even though products looked more similar than Acthar/Synacthen.” Questcor Pharmaceuticals closed on Monday at $56.26.
Posted In: Analyst ColorReiterationAnalyst RatingsMario CorsoMizuho Securities USA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...